Anna Levin, MD
Dermatology · Quincy, ILNPI 1255621496
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.7% of the total.
Across 358 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$891
- Incyte Corporation$364
- Pfizer$256
- UCB, Inc.$218
- Sanofi$210
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,82798%
- Education$802%
- Other$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 136 | $1,513 |
| Sun Pharmaceutical Industries Inc. | 63 | $891 |
| Incyte Corporation | 38 | $364 |
| Pfizer | 20 | $256 |
| UCB, Inc. | 11 | $218 |
| Sanofi | 9 | $210 |
| Regeneron Healthcare Solutions, Inc. | 8 | $186 |
| LEO Pharma Inc. | 5 | $160 |
| Johnson & Johnson | 7 | $136 |
| Amgen | 8 | $129 |
| Organon | 11 | $126 |
| E.r. Squibb & Sons, L.L.C. | 5 | $116 |
| Lilly USA, LLC | 6 | $101 |
| Novartis | 5 | $81 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Prugen, Inc. Pharmaceuticals | 5 | $72 |
| Galderma Laboratories, L.p. | 5 | $62 |
| Bristol Myers Squibb | 3 | $52 |
| Merck | 2 | $29 |
| Elite Orthopedics, LLC | 1 | $26 |
| Welch Allyn | 2 | $24 |
| Sensus Healthcare, Inc. | 1 | $21 |
| Botanix SB Inc | 1 | $19 |
| Dermavant Sciences, Inc. | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Biofrontera Inc. | 2 | $14 |
| Merz North America, Inc. | 1 | $12 |
How this compares
$4,931 in reported general payments places this provider in the 65th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 13 | $268,774 |
| Humira(Cf) PenAdalimumab | 13 | $165,733 |
| Dupixent SyringeDupilumab | 21 | $94,353 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $80,798 |
| Clobetasol Propionate | 110 | $5,270 |
| Pimecrolimus | 14 | $4,258 |
| ValacyclovirValacyclovir Hcl | 44 | $2,605 |
| Doxycycline Hyclate | 100 | $2,286 |
| Metronidazole | 33 | $2,253 |
| Ketoconazole | 145 | $2,230 |
| Betamethasone Dipropionate | 88 | $2,143 |
| Triamcinolone Acetonide | 91 | $1,085 |
| Doxycycline Monohydrate | 19 | $582 |
| Halobetasol Propionate | 11 | $466 |
| Clindamycin Phosphate | 15 | $391 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Quincy
- Ahmad AminNaperville$4.1M
- Raj ChovatiyaChicago$3.6M
- George LewittNorthbrook$3M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
- Melissa AbramsVernon Hills$600K
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
- Emily RubensteinLincolnshire$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.